Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced plans to hold a R&D update on May 15, 2024 at 14:00 CEST to present its CORIST program and the recent Phase IIa results with SCO-101 in metastatic colorectal cancer, and inform more about the planned rights issue.
Live and on-site Investor/R&D Event
The event will be broadcasted live and there will be the opportunity to ask questions and to join the event in person. If you wish to register to participate in the event on site, please send an email to ir@scandiononcology.com
Link to webcast: https://www.youtube.com/watch?v=H_3WsiEh37c
Time: May 15, 14:00 CEST
Venue: Infront Direkt Studios, Kungsgatan 33 (2nd floor), Stockholm
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
About Scandion Oncology
Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.